J 
Johnson & Johnson JNJ · USD
Health Care · Pharmaceuticals · US listing · 🇺🇸 United States
S&P 500Dow Jones
276.22
+1.43%
Close of 6 Nov 2026, in USD
At a glance
Figures in USD, from our data supplier.
Revenue
$94.19bn
FY2016FY2025
Net income
$26.80bn
FY2016FY2025
Free cash flow
$19.70bn
FY2016FY2025
Shareholders' equity
$81.54bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $94.19bn | $88.82bn | $85.16bn | $79.99bn | $78.74bn | $82.58bn | $82.06bn | $81.58bn | $76.45bn | $71.89bn |
| Gross profit | $68.56bn | $61.35bn | $58.41bn | $55.39bn | $55.34bn | $54.16bn | $54.50bn | $54.49bn | $51.01bn | $50.10bn |
| Research and development | $14.66bn | $17.23bn | $15.05bn | $14.13bn | $14.28bn | $12.34bn | $11.36bn | $10.78bn | $10.59bn | $9.14bn |
| Operating income | $25.60bn | $22.15bn | $21.85bn | $21.01bn | $20.94bn | $19.73bn | $20.97bn | $21.18bn | $18.90bn | $20.89bn |
| Net income | $26.80bn | $14.07bn | $35.15bn | $17.94bn | $20.88bn | $14.71bn | $15.12bn | $15.30bn | $1.30bn | $16.54bn |
| Diluted earnings per share | 10.99 | 5.80 | 14.46 | 6.73 | 7.82 | 5.51 | 5.66 | 5.62 | 0.48 | 5.98 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $199.21bn | $180.10bn | $167.56bn | $187.38bn | $182.02bn | $174.89bn | $157.73bn | $152.95bn | $157.30bn | $141.21bn |
| Cash and short-term investments | $20.10bn | $24.52bn | $22.93bn | $22.28bn | $31.61bn | $25.18bn | $19.29bn | $19.69bn | $18.30bn | $41.91bn |
| Total liabilities | $117.67bn | $108.61bn | $98.78bn | $110.57bn | $108.00bn | $111.62bn | $98.26bn | $93.20bn | $97.14bn | $70.79bn |
| Debt | $47.93bn | $36.63bn | $29.33bn | $39.64bn | $33.75bn | $35.27bn | $27.70bn | $30.48bn | $34.58bn | $27.13bn |
| Shareholders' equity | $81.54bn | $71.49bn | $68.77bn | $76.80bn | $74.02bn | $63.28bn | $59.47bn | $59.75bn | $60.16bn | $70.42bn |
| Shares outstanding | 2,439m | 2,427m | 2,431m | 2,664m | 2,670m | 2,669m | 2,669m | 2,724m | 2,685m | 2,765m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | $24.53bn | $24.27bn | $22.79bn | $21.19bn | $23.41bn | $23.54bn | $23.42bn | $22.20bn | $21.06bn | $18.77bn |
| Capital spending | −$4.83bn | −$4.42bn | −$4.54bn | −$4.01bn | −$3.65bn | −$3.35bn | −$3.50bn | −$3.67bn | −$3.28bn | −$3.23bn |
| Free cash flow | $19.70bn | $19.84bn | $18.25bn | $17.18bn | $19.76bn | $20.19bn | $19.92bn | $18.53bn | $17.78bn | $15.54bn |
| Dividends paid | −$12.38bn | −$11.82bn | −$11.77bn | −$11.68bn | −$11.03bn | −$10.48bn | −$9.92bn | −$9.49bn | −$8.94bn | −$8.62bn |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $25.31bn | $24.06bn | $24.56bn | $23.99bn | $23.74bn | $21.89bn | $22.52bn | $22.47bn |
| Gross profit | $18.50bn | $17.20bn | $16.60bn | $16.70bn | $16.13bn | $14.54bn | $15.41bn | $15.51bn |
| Operating income | $7.17bn | $6.39bn | $5.11bn | $7.38bn | $7.02bn | $6.66bn | $3.82bn | $5.79bn |
| Net income | $5.53bn | $5.24bn | $5.12bn | $5.15bn | $5.54bn | $11.00bn | $3.43bn | $2.69bn |
| Diluted earnings per share | 2.27 | 2.15 | 2.10 | 2.12 | 2.29 | 4.54 | 1.41 | 1.11 |
| Cash from operations | — | $2.51bn | $7.31bn | $9.17bn | $3.88bn | $4.17bn | $6.98bn | $7.99bn |
| Capital spending | — | −$1.05bn | −$1.84bn | −$788.0m | −$1.40bn | −$795.0m | −$2.15bn | −$2.28bn |
| Free cash flow | — | $1.47bn | $5.47bn | $8.38bn | $2.48bn | $3.38bn | $4.84bn | $5.71bn |
| Total assets | — | $200.89bn | $199.21bn | $192.82bn | $193.39bn | $193.67bn | $180.10bn | $178.29bn |
| Cash and short-term investments | — | $22.05bn | $20.10bn | $18.56bn | $18.88bn | $38.78bn | $24.52bn | $20.30bn |
| Debt | — | $54.99bn | $45.93bn | $43.81bn | $47.73bn | $49.26bn | $34.88bn | $33.29bn |
| Shareholders' equity | — | $81.19bn | $81.54bn | $79.28bn | $78.47bn | $78.11bn | $71.49bn | $70.16bn |
Financial ratios
Data as of 31 Aug 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Gross margin | 72.8% | 69.1% | 68.6% | 69.3% | 70.3% | 65.6% |
| Operating margin | 27.2% | 24.9% | 25.7% | 26.3% | 26.6% | 23.9% |
| Net margin | 28.5% | 15.8% | 41.3% | 22.4% | 26.5% | 17.8% |
| Return on equity | 32.9% | 19.7% | 51.1% | 23.4% | 28.2% | 23.3% |
| Return on assets | 13.5% | 7.8% | 21.0% | 9.6% | 11.5% | 8.4% |
| Free cash flow yield | 4.5% | 4.4% | 4.2% | 3.5% | 3.8% | 3.8% |
| Revenue growth | 6.0% | 4.3% | 6.5% | 1.6% | -4.7% | 0.6% |
| Earnings growth | 90.6% | -60.0% | 95.9% | -14.1% | 41.9% | -2.7% |
| Current ratio | 1.03x | 1.11x | 1.16x | 0.99x | 1.35x | 1.21x |
| Debt to equity | 0.59x | 0.51x | 0.43x | 0.52x | 0.46x | 0.56x |
| Equity ratio | 40.9% | 39.7% | 41.0% | 41.0% | 40.7% | 36.2% |
| Interest coverage | 26.36x | 29.34x | 17.52x | 76.13x | 114.44x | 98.17x |
| R&D as a share of sales | 15.6% | 19.4% | 17.7% | 17.7% | 18.1% | 14.9% |
| Buybacks as a share of market value | -0.5% | 0.1% | 8.8% | 0.2% | -0.0% | -0.0% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 5.6% | 2.7% | 3.0% |
| Operating income | 6.8% | 5.3% | 3.4% |
| Net income | 14.3% | 12.7% | 5.7% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 71.0% | 70.0% | 69.3% | 68.6% |
| Operating margin | 26.1% | 26.0% | 25.8% | 26.0% |
| Net margin | 22.3% | 27.0% | 25.4% | 21.7% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 18.8 | 24.9 | 10.8 | 26.2 | 21.9 | 28.6 | 25.8 | 23.0 | 288.6 | 19.3 |
| Price to sales | 5.4 | 4.0 | 4.5 | 5.9 | 5.8 | 5.1 | 4.7 | 4.3 | 4.9 | 4.4 |
Market value over time
30 Sept 2016 to 28 Aug 2026, in USD
$328.99bn$654.04bn
Share price return
Finished calendar years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Return | 44% | -7% | -11% | 5% | 10% | 5% | 14% | -9% | 22% | 15% |
Dividends and splits
Per share, in the currency the company pays
Paid for 62 years. Last went ex-dividend on 25 Aug 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 3.98 | 5.14 | 4.91 | 4.70 | 4.45 | 4.19 | 3.98 | 3.75 |
- 1-to-1 reverse split · 23 Aug 2023
- 1-to-1 reverse split · 21 Aug 2023
- 2-for-1 split · 13 Jun 2001
- 2-for-1 split · 12 Jun 1996
- 2-for-1 split · 10 Jun 1992
- 2-for-1 split · 11 May 1989
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.